Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'

• References

• 1 Grines CL, Bonow RO, Casey Jr DE. et al. American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-739.
• 2 ACTIVE Writing Group of the ACTIVE Investigators. Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
• 3 Rogacka R, Chieffo A, Michev I. et al. Dual anti-platelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J Am Coll Cardiol Intv 2008; 01: 56-61.
• 4 Manzano-Fernández S, Pastor FJ, Marín F. et al. Increased major bleeding complications related to triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary artery disease. Chest. 2008 in press.
• 5 Ruiz-Nodar JM, Marín F, Hurtado JA. et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-825.
• 6 Karjalainen PP, Porela P, Ylitalo A. et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-732.
• 7 Nguyen MC, Lim YL, Walton A. et al. for the GRACE Investigators. Combining warfarin and anti-platelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. Eur Heart J 2007; 28: 1717-1722.
• 8 Rubboli A, Halperin JL, Airaksinen KE. et al. Antithrombotic therapy in p-atients treated with oral anticoagulation undergoing coronary stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008 in press.
• 9 May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.
• 10 Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98: 980-987.
• 11 Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use inpatients with atrial fibrillation undergoing percutaneous coronary intervention. The need for consensus and a management guideline. Chest 2006; 130: 1823-1827.
• 12 Chan FK, Ching JY, Hung LC. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-244.